Table 5.
Study characteristics of acute and chronic human studies assessing the impact of red wine polyphenols on systolic and diastolic blood pressure
| Author | Year | Study design | Health status | Number of participants | Mean age (years) | Sex (%F) | BMI (kg/m2) | Duration (days) | Wash out (days) | Supplement | Dose (mg/day) | Systolic blood pressure (mmHg) | Diastolic blood pressure (mmHg) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control baseline/final (mean ± SD) | Supplement baseline/final (mean ± SD) | Control baseline/final (mean ± SD) | Supplement baseline/final (mean ± SD) | ||||||||||||
| Bhatt et al. | 2012 | P | T2DM |
Control: 29 Supp: 28 |
57.2 | 46.9 | 24.8 | 90 | NA | RSV | 250 | 134.5 ± 14.6/142.3 ± 13 | 139.7 ± 16.1/127.9 ± 15.4 | 78.6 ± 10.9/85.7 ± 9.1 | 81.4 ± 9.6/79.3 ± 9.7 |
| Botden et al. | 2012a | X | HT |
Control: 61 Supp: 61 |
61 | 24.6 | 27 | 28 | 7 | Provinol | 280 | 145 ± 12/143 ± 2 | 145 ± 12/143 ± 2 | 86 ± 8/83 ± 1 | 86 ± 8/84 ± 1 |
| 2012b | X | HT |
Control: 61 Supp: 61 |
61 | 24.6 | 27 | 28 | 7 | Provinol | 560 | 145 ± 12/143 ± 2 | 145 ± 12/142 ± 2 | 86 ± 8/83 ± 1 | 86 ± 8/83 ± 1 | |
| Draijer et al. | 2015a | X | HT |
Control: 28 Supp:28 |
57.6 | 45 | 26.3 | 28 | 0 | GE + GSE | 550 | 139.9 ± 12.2/138.9 ± 1.3 | 139.9 ± 2.2/135.9 ± 1.3 | 84.8 ± 8.3/86.6 ± 1.2 | 84.8 ± 8.3/84.7 ± 0.8 |
| 2015b | X | HT |
Control: 28 Supp: 29 |
57.6 | 45 | 26.3 | 28 | 0 | GE | 800 | 139.9 ± 12.2/132.1 ± 1.4 | 139.9 ± 12.2/131.8 ± 1.3 | 84.8 ± 8.3/79.6 ± 0.6 | 84.8 ± 8.3/79.0 ± 0.6 | |
| Faghihzadeh et al. | 2015 | P | NAFLD |
Control: 25 Supp: 25 |
45.2 | 30 | 28.6 | 84 | NA | RSV | 500 | 116.4 ± 14.0/112.9 ± 14.5 | 119.0 ± 13.8/104.8 ± 12.4 | 78.0 ± 8.4/74.4 ± 8.6 | 79.7 ± 8.4/72.8 ± 9.9 |
| Fodor et al. | 2018a | P | S |
Control: 92 Supp: 81 |
64.9 | 39.9 | 29.7 | 364 | NA | RSV | 100 | 148.4 ± 15.2/145.3 ± 15.3 | 148.0 ± 15.3/139.9 ± 14.8 | 87.6 ± 11.3/85.7 ± 11.1 | 88.3 ± 10.7/84.3 ± 10.2 |
| 2018b | P | S |
Control: 92 Supp: 55 |
64.7 | 39.2 | 29.7 | 364 | NA | RSV | 200 | 148.4 ± 15.2/145.3 ± 15.3 | 149.2 ± 15.1/139.4 ± 14.8 | 87.6 ± 11.3/85.7 ± 11.1 | 88.5 ± 11.1/84.1 ± 10.8 | |
| Fujitaka et al. | 2011a | P | MS |
Control: 17 Supp: 17 |
63 | 29.4 | 26.1 | 90 | NA | RSV | 100 | 131 ± 15/129 ± 13 | 129 ± 14/127 ± 14 | 74 ± 12/73 ± 14 | 73 ± 6/76 ± 10 |
| 2011b | P | MS |
Control: 17 Supp: 17 |
62 | 23.5 | 27.9 | 90 | NA | RSV | 100 | 131 ± 15/129 ± 13 | 129 ± 13/133 ± 8 | 74 ± 12/73 ± 14 | 73 ± 14/76 ± 15 | |
| Heeboll et al. | 2016 | P | NAFLD |
Control: 13 Supp: 13 |
43.4 | 34.6 | 32.1 | 180 | NA | RSV | 500 | 136 ± 15/140 ± 13 | 142 ± 15/137 ± 16 | 79 ± 8/84 ± 9 | 89 ± 8/85 ± 10 |
| Immamura et al. | 2017 | P | T2DM |
Control: 25 Supp: 25 |
57.8 | 48 | 25.1 | 84 | NA | RSV | 100 | 137.1 ± 25.0/133.2 ± 26.5 | 137.1 ± 18.7/131.6 ± 16.5 | 80.8 ± 11.5/79.9 ± 11.5 | 82.0 ± 9.5/80.5 ± 11.2 |
| Khodabandehloo et al. | 2018 | P | T2DM |
Control: 20 Supp: 25 |
58.9 | 49 | 29.6 | 160 | NA | RSV | 800 | 129.2 ± 15.9/126.8 ± 8.2 | 126.9 ± 9.2/116.9 ± 8.4 | 74.7 ± 8.3/77.0 ± 8.5 | 76.8 ± 8.1/70.7 ± 8.2 |
| Kjaer et al. | 2017a | P | MS |
Control: 24 Supp: 21 |
48.5 | M | 33.8 | 126 | NA | RSV | 150 | 150.0 ± 3.4/142.0 ± 2.5 | 140.0 ± 2.3/145.0 ± 2.6 | 91.3 ± 2.1/86.0 ± 1.3 | 86.9 ± 1.5/87.7 ± 1.4 |
| 2017b | P | MS |
Control: 24 Supp: 21 |
49.9 | M | 34 | 126 | NA | RSV | 1000 | 150.0 ± 3.4/142.0 ± 2.5 | 146.0 ± 2.3/140.0 ± 2.6 | 91.3 ± 2.1/86.0 ± 1.3 | 89.3 ± 1.7/87.8 ± 1.4 | |
| Marques et al. | 2018 | X | ED |
Control: 24 Supp: 24 |
54 | 58 | 30 | 0 | 7 | RSV | 300 | 139 ± 1/141 ± 3 | 142 ± 2/145 ± 3 | 87 ± 1/88 ± 2 | 87 ± 2/88 ± 3 |
| Mellen et al. | 2010 | X | Pre-MS |
Control: 50 Supp: 50 |
52.1 | 50 | 29.8 | 28 | 28 | RSV | 1300 | 124.6 ± 1.8/123.2 ± 1.0 | 122.4 ± 1.6/125.2 ± 2.0 | 75.3 ± 1.2/72.8 ± 1.1 | 72.8 ± 1.2/73.2 ± 1.3 |
| Movahed et al. | 2013 | P | T2DM |
Control: 33 Supp: 33 |
52.1 | 50 | 27.4 | 45 | NA | RSV | 1000 | 129.3 ± 15.2/130.7 ± 13.2 | 129.0 ± 14.9/121.5 ± 10.3 | 78.6 ± 15.4/81.6 ± 5.8 | 78.6 ± 15.4/78.5 ± 6.4 |
| Perez-Jiminez et al. | 2008 | P | HC |
Control: 9 Supp: 34 |
35.1 | 60.1 | 24.4 | 126 | NA | GADF | 7500 | 121.5 ± 14.0/113.7 ± 9.4 | 126.5 ± 22.1/118.0 ± 19.6 | 71.4 ± 14.4/71.3 ± 8.7 | 78.2 ± 11.7/74.4 ± 12.1 |
| Ras et al. | 2013 | P | HT |
Control:35 Supp: 34 |
63.7 | 45.7 | 25.5 | 56 | NA | GSE | 300 | 135.7 ± 1.7/132.5 ± 1.7 | 135.8 ± 1.9/130.3 ± 1.7 | 81.1 ± 1.2/80.0 ± 1.1 | 81.9 ± 1.5/79.1 ± 1.3 |
| Sano et al. | 2007a | P | Healthy |
Control: 20 Supp: 21 |
52.1 | 51.2 | 24.3 | 84 | NA | GSE | 200 | 122.7 ± 4.4/127.8 ± 4.8 | 126.4 ± 3.0/129.2 ± 3.2 | 77.1 ± 2.6/81.1 ± 2.8 | 77.9 ± 1.7/79.6 ± 2.0 |
| 2007b | P | Healthy |
Control: 20 Supp: 21 |
52.1 | 51.7 | 24.3 | 84 | NA | GSE | 400 | 122.7 ± 4.4/127.8 ± 4.8 | 126.2 ± 4.0/127.7 ± 3.0 | 77.1 ± 2.6/81.1 ± 2.8 | 78.0 ± 2.5/79.5 ± 2.0 | |
| Seyyedebrahimi et al. | 2018 | P | T1DM |
Control: 18 Supp: 23 |
56.8 | 53.9 | 28.9 | 60 | NA | RSV | 800 | 129.2 ± 18.2/127.6 ± 12.3 | 130.0 ± 15.9/113.3 ± 15.9 | 76.7 ± 8.1/77.0 ± 8.1 | 76.7 ± 7.9. 72.3 ± 4.1 |
| Sivaprakasapillai et al. | 2009a | P | MS |
Control: 9 Supp: 9 |
45.5 | 61.1 | 36 | 28 | NA | GSE | 150 | 123 ± 4/121 ± 4 | 134 ± 5/123 ± 4 | 74 ± 4/70 ± 4 | 83 ± 3/77 ± 2 |
| 2009b | P | MS |
Control: 9 Supp: 9 |
46.5 | 61.1 | 36.5 | 28 | NA | GSE | 300 | 123 ± 4/121 ± 4 | 127 ± 4/116 ± 3 | 74 ± 4/70 ± 4 | 78 ± 3/71 ± 3 | |
| Timmers et al. | 2011 | X | O |
Control: 11 Supp: 11 |
64 | M | 30.5 | 30 | 30 | RSV | 150 | 131.0 ± 3.1/130.5 ± 2.7 | 132.0 ± 3.0/124.7 ± 3.1 | 82.0 ± 2.5/81.6 ± 2.8 | 83.0 ± 0.2/80.0 ± 2.9 |
| Timmers et al. | 2016 | X | T2DM |
Control: 17 Supp: 17 |
52.5 | M | 31.5 | 30 | 28 | RSV | 150 | 142.0 ± 3.9/141.0 ± 2.8 | 139.0 ± 4.2/138.0 ± 2.9 | 87.0 ± 2.7/86.0 ± 1.9 | 85.0 ± 2.7/86.0 ± 1.9 |
| Tome-Carneiro et al. | 2013 | P | T2DM |
Control: 9 Supp: 13 |
58.5 | M | 31.4 | 364 | NA | GE | 700 | 129 ± 21/139 ± 23 | 129 ± 20/137 ± 24 | 74 ± 13/77 ± 9 | 73 ± 9/74 ± 11 |
| Van der Made et al. | 2017 | X | O |
Control: 45 Supp: 45 |
60 | 44.4 | 28.8 | 28 | 28 | RSV | 150 | 136 ± 17/130 ± 18 | 136 ± 17/132 ± 17 | 88 ± 9/84 ± 9 | 88 ± 9/96 ± 9 |
| Van Mierlo et al. | 2010a | X | Healthy |
Control: 35 Supp: 35 |
31.4 | M | 23.2 | 14 | 7 | GE | 1405 | 123.0 ± 10.5/118.6 ± 1.2 | 123.0 ± 10.5/121.7 ± 14.5 | 72.6 ± 9.2/70.8 ± 1.0 | 72.6 ± 92/71.0 ± 12.4 |
| 2010b | X | Healthy |
Control: 35 Supp: 35 |
31.4 | M | 23.2 | 14 | 7 | GSE | 2547 | 123.0 ± 10.5/118.6 ± 1.2 | 123.0 ± 10.5/122.4 ± 14.5 | 72.6 ± 9.2/70.8 ± 1.0 | 72.6 ± 9.2/72.0 ± 11.7 | |
| Wightman et al. | 2014a | X | Healthy |
Control: 23 Supp: 23 |
21 | 82.6 | 24.2 | 0 | 2 | RSV | 250 | 113.2 ± 11.1/116.6 ± 7.2 | 112.0 ± 9.5/114.4 ± 6 | 76.9 ± 11.9/77.6 ± 6.0 | 75.7 ± 8.0/78.2 ± 3.1 |
| 2014b | X | Healthy |
Control: 23 Supp: 23 |
21 | 82.6 | 24.2 | 0 | 2 | RSV + P | 270 | 113.2 ± 11.1/116.6 ± 7.2 | 114.2 ± 9.5/115.6 ± 6.0 | 76.9 ± 11.9/77.6 ± 6.0 | 75.1 ± 8/79.9 ± 3.1 | |
| Wong et al. | 2013 | X | O |
Control: 28 Supp: 28 |
61 | 57.1 | 33.3 | 42 | 0 | RSV | 75 | 127.4 ± 2.4/128.8 ± 2.8 | 127.4 ± 2.4/127.6 ± 2.9 | 73.3 ± 1.3/74.4 ± 1.7 | 73.3 ± 1.3/74.2 ± 1.4 |
| Xue et al. | 2016 | X | O |
Control: 29 Supp: 29 |
45 | 72.4 | 34.1 | 56 | 42 | RSV + HESP | 210 | 131.0 ± 2.0/132.0 ± 3.0 | 131.0 ± 3.0/133.0 ± 3.0 | 81.7 ± 1.9/82.9 ± 2.3 | 83.4 ± 2.1/83.3 ± 2.3 |
| Yoshino et al. | 2012 | P | Healthy |
Control: 15 Supp: 16 |
59 | F | 24.3 | 84 | NA | RSV | 75 | 123 ± 15/121 ± 14 | 118 ± 16/119 ± 16 | 65 ± 10/63 ± 9 | 67 ± 11/72 ± 10 |
X cross-over, P parallel arm, T2DM type 2 diabetes melliutus, HT hypertension, NAFLD non-alcoholic fatty liver disease S stroke, MS metabolic syndrome, ED endothelial dysfunction, O Obese, RSV resveratrol, GE grape extract, GSE grape seed extract, GADF grape antioxidant dietary fibre, P Piperine, HESP hesperetin